



Docket No. PRD2052USNP

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. J. Renzi et al. Confirma

Confirmation No.: 9072

Serial No. : 10/810,755

Art Unit: 1646

Filed

: March 26, 2004

Examiner:

For

: Use of Erythropoietin in Stroke Recovery

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 22, 2005 (Date of Deposit)

Myra H. McCormack
(Name of applicant, assignee, or Registered Representative)

/Myra H. McCormack/
(Signature)

November 22, 2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

$\boxtimes$ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set fortl
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
<u> </u>
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with   the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
The accordance with 51 07/a) this Information
In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or

	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
	In accordance with §1.97(d), this Information
Disclosur	Statement is being filed after the mailing date of
	inal Action under §1.113 or a Notice of Allowance
	311 but before the payment of the Issue Fee.
	s) hereby petition(s) for consideration of this
	n Disclosure Statement. Included are: Statement in
	with §1.97(e) as set forth below and the fee of
<u>φτου.υυ</u> αι	set forth in §1.17(p).
	Copies of each of the references listed on the
attached 1	orm PTO-1449 are enclosed herewith.
_	
	Copies of only foreign patent documents and non-
-	erature are enclosed in accordance with 37 CFR 1.98
	The U.S. patents and each U.S. patent application
	n listed on the attached Form PTO-1449 are not
	ecause this U.S. patent application was filed after
	003 or this international application has entered the
	tage under 35 USC §371 after June 30, 2003 (see USPTO
waiver of	requirement under 37 CFR 1.98 (a)(2)(i).
_	
□.	There are no listed references which are not in the
English la	nguage.
-	
	The relevance of those listed references which are
	English language is as follows: CA2352553A1 is an
	nguage equivalent of WO00/35475. See International
Search Rep	ort for relevance.

$\boxtimes$	Attached	are co	pies of	searc	h rep	ort (s	) from	1	
correspond	ding pater	t appl	ication	(s), w	hich	are li	isted	on	the
attached s	Submission	Under	MPEP 6	09 D.					

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2052/MHM. This form is submitted in triplicate.

Respectfully submitted,

/Myra H. McCormack/ Myra H. McCormack Reg. No. 36,602 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATED: November 22, 2005

Under the Panerwork Reduction Act of 1995, no persons are required to

PTO/S8/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

stitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

micabour ma conoccour or anounteness must	ass a displays a valo offic control lighter.
Confirmation Number	9072
Application Number	10/810,755
Filing Date	03/26/2004
First Named Inventor	Michael J. Renzi
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	PRD2052USNP

<u> </u>	Ī	U.S. Patent Docume	ent	U.S. PATENT DOCUMENTS		
Exem Initials	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6121246	А	Isner	09/19/2000	
		6165783	A	Weiss et al	12/26/2000	
				h. d.		
• • • • • • • • • • • • • • • • • • • •						
	-	<u> </u>		I FOREIGN PATENT DOCUMENTS	1	l

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, Date of Publication of where relevant Name of Patentee or Cite Cited Document Exam passages or relevant T٥ **Applicant of Cited Document** figures appear Office<sup>3</sup> Number<sup>4</sup> KindCode<sup>5</sup> mm-dd-yyyy No.1 CA 2 353 553 **A1** Ehrenreich 06-22-2000 WO **A2** 00/35475 Ehrenreich 06-22-2000 **English Abstract** No

Examiner	Date	
Signature		
Orginolano	Consucied	

<sup>&</sup>quot;EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

9072
10/810,755
03/26/2004
Michael J. Renzi
1646

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, seind; symposium, catalog, etc.), date, page(s), votumelssue number(s), publisher, city and/or country where published    Ehrenreich H, et. al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.   Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.   Hernander TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324   Junk RA, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.   Nasuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493   Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116   Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392   Friller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002;21:0391-10301.   Ruscher K, et. al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bel-xl and bel-2. Blood. 1996;88:1576-1582   Siren AL, et al., Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Net). 2001;93:4044-049.   Wen TC, et al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bel-xl expression. J Neurosci Res. 2002;67:795-803   Zimmerman GA, et al. Neurotoxicity	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Initials* No.!  Ehrenreich H, et. al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.  Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.  Hernandez TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324  Junk AK, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:1948-19493  Morishia et al., "Brythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bclxl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al., Erythropoietin protects neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Bernaudin, Myriam, et al. A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Bode flow a	F	0"-	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	+2	
Ehrenreich H, et. al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.  Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:4950-9455.  Hernandez TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324  Junk AK, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19408-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Rippocampal and Cerebral Cortical Neurons, and Erythropoietin Provents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin productions in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin and promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al.; Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:793-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal				1-	
Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.  Hernandez TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324  Junk AK, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin reprevents in Numan cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al., Erythropoietin prevents neuronal apoptosis after cerebral ischemic hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;99:4044-4049.  Wen TC, et al., Erythropoietin protects neuronal apoptosis after cerebral ischemia injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;69:755-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of a			\$ <del></del>		
injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.  Hernandez TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324  Junk AK, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582.  Siren AL, et al., Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al., Erythropoietin provents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-6049.  Wen TC, et al., Erythropoietin provents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-6049.  Wen TC, et al., Erythropoietin provents neuronal apoptosis after cerebral ischemia of hypoxia and cerebral ischemia in Mince, Journal of Cerebral Blood flow and Netabolism, 1999, 19-643-651  Digicayloglu, M et			both safe and beneficial. Mol Med. 2002;8:495-505.		
Exp Neurol. 1988;102:318-324  Junk AK, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin provents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al. A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaling cascades, Nature 2001 Vol. 412  J			injury and markedly enhances neurological recovery from experimental spinal		
acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659- 10664.  Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin provents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:1044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoquanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaling dascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin mediated neuroprotection involves cross-talk between Jak2 and NF- kB signaling					
production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493  Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neuronal apoptosis and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al., A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-KB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.		
and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116  Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bel-xl and bel-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bel-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493		
neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392  Priller J, et. al., Inflammation in strokea potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157  Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;01:271-276  Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF- kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116		
Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392		
tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.  Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157		
repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582  Siren AL, et al.; Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Diglcaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.		
ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276  Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Diglcaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582		
ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.  Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1		•	ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276		
cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803  Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Diglcaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.		
focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748  Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803		
Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651  Diglcaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1			focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad		
kB signaling cascades, Nature 2001 Vol. 412  Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous  System, Pediatric Research, 1998, Vol. 43 No 1			Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and		
System, Pediatric Research, 1998, Vol. 43 No 1			Digicaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-		
Koshimura, K. et al, Effects of Erythropoletin on Neuronal Activity, Journal of Neurochemistry, 1999			System, Pediatric Research, 1998, Vol. 43 No 1		
			Koshimura, K. et al, Effects of Erythropoletin on Neuronal Activity, Journal of Neurochemistry, 1999		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 3 of 3

to tropone to a concountry of anomiconount	mileto il deperto o illia omi odi indi indi.
Confirmation Number	9072
Application Number	10/810,755
Filing Date	03/26/2004
First Named Inventor	Michael J. Renzi
Group Art Unit	1646
Examiner Name	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
nitials*	No.1	publisher, city and/or country where published	,
	113	Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts	·
		during focal stroke and neuroprotective effects of aminoguanidine.	
		Proc Natl Acad Sci U S A. 1995; 92: 3744-3748	
		Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in	
		Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood	
		flow and Metabolism, 1999, 19-643-651	
	<del></del>	Diglcaylioglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between	
		Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412	
		Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central	
		Nervous System, Pediatric Research, 1998, Vol. 43 No 1	
		Koshimura, K. et al, Effects of Erythropoietin on Neuronal Activity, Journal of Neurochemistry, 1999	
		Masuda, S. et. al. Funcional Erythropoietin Receptor of the Cells with Neural Characteristics,	
		The Journal of Biological Chemistry, 1993, Vol. 268 No 15 pp. 11208-11216	
		Namura, S. et al, Intravenoous administration of MEK inhibitor U0126 affords brain protection	
		against forebrain ischemia and focal cerebral ischemia, PNAS 2001, vol. 98 no. 20 pp. 11569-	
		11574	
		Murray, B. et al, Inhibition of the p44/42 MAP Kinase pathway protects hippocampal neurons	
		in a cell-culture model of seizure activity, Proc. Natl Acad. Sci, 1998, Vol. 95 pp. 11974-11980	
		Alafaci, C. et al. Effects of recombinant human erythropoietin on cerebral ischemia following	
		experimental suarachnoid hemorrhage, European Journal of Pharmacology, 406 (2000) 219-	
		225	
		Alessandrini, A. et al, MEK1 protein kinase inhibition protects against damage resulting from	
		focal cerebral ischemia, PNAS 1999 Vol 96 No 22 pp. 12866-12869	
		Sinor, A., Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and	
		AMPA toxicity, Neuroscience Letters 290 (2000) 213-215	
		Sakanaka, Masahiro, In vivo evidence that erythropoietin protects neurons from ischemic	<del></del>
		damage, Proc Natl Acad Sci, 1998 Vol. 95 pp. 4635-4640	
		Ribatt, D. et al, Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured	
i		Endothelial Cells and Stimulates Neovascularization In Vivo, Blood, 1999 Vol 98 No 8 pp	
		2627-2636	
	-	Westenfelder, C. et al, Human, rat, and mouse kidney cells express functional	
Ì		erythropoietin receptors, Kidney International, 1999 Vol 55, pp. 808-820	
		erytriropoleun receptors, Nidney International, 1999 Vol 55, pp. 808-820	
		***************************************	<del></del>

Examiner		Date	
Signature	<u> </u>	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

### SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Confirmation Number	9072	
Application Number	10/810,755	
Filing Date	03/26/2004	
First Named Inventor	Michael J. Renzi	
Group Art Unit	1646	
Examiner Name		
Attorney Docket Number	PRD2052USNP	

U.S. PATENT DOCUMENTS

			U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
Examiner Cite Initials No.1		Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)	
		· · · · · · · · · · · · · · · · · · ·	<del>                                     </del>		
	-	<del></del>			
		5005	IGN PATENT DOCU		

Pages, Columns, Lines, where relevant passages Foreign Patent Document Name of Patentee or Examiner Cite or relevant figures Applicant of Cited Document Number<sup>4</sup> KindCode<sup>5</sup> OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s). Cite No.1 Examiner T<sup>2</sup> volume-issue number(s), publisher, city and/or country where published Initials\* International Search Report dated March 7, 2005, for corresponding international application PCT/US04/09443.

Examiner	Date	
Signature	Considered	